BRAF and NRAS mutations in Russian melanoma patients: results of a nationwide study-Reference-Cited by-同舟云学术

BRAF and NRAS mutations in Russian melanoma patients: results of a nationwide study

Published:2016-10 Issue:5 Volume:26 Page:442-447
ISSN:0960-8931
Container-title:Melanoma Research
language:en
Short-container-title:

Author:

Frank Georgiy A.,Aleksakhina Svetlana N.,Zavalishina Larisa E.,Kekeyeva Tatiana V.,Venina Aigul R.,Ivantsov Alexandr O.,Mitiushkina Natalia V.,Moiseyenko Alla V.,Pfeifer Werner,Strelkova Tatiana N.,Imyanitov Evgeny N.

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Cancer Research,Dermatology,Oncology

Reference48 articles.

1. Mutations of the BRAF gene in human cancer;Davies;Nature,2002

2. Vemurafenib: the first drug approved for BRAF-mutant cancer;Bollag;Nat Rev Drug Discov,2012

3. Targeting RAF kinases for cancer therapy: BRAF-mutated melanoma and beyond;Holderfield;Nat Rev Cancer,2014

4. EGF receptor gene mutations are common in lung cancers from ‘never smokers’ and are associated with sensitivity of tumors to gefitinib and erlotinib;Pao;Proc Natl Acad Sci USA,2004

5. Activation of N-ras in a human melanoma cell line;Padua;Mol Cell Biol,1985

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Real-world efficacy of the first line therapy with prolgolimab in patients with metastatic melanoma: interim results of the FORA (FOrteca Real practice Assessment) observational study;Journal of Modern Oncology;2023-02-01

2. Content of circulating tumor DNA depends on the tumor type and the dynamics of tumor size, but is not influenced significantly by physical exercise, time of the day or recent meal;Cancer Genetics;2021-08

3. BRAF and NRAS mutations and antitumor immunity in Korean malignant melanomas and their prognostic relevance: Gene set enrichment analysis and CIBERSORT analysis;Pathology - Research and Practice;2019-12

4. Lack of Response to Vemurafenib in Melanoma Carrying BRAF K601E Mutation;Case Reports in Oncology;2019-05-16

5. Molecular Tests for the Choice of Cancer Therapy;Current Pharmaceutical Design;2017-12-21